Trade Names:Emend- Capsules 40 mg- Capsules 80 mg- Capsules 125 mg
Selective high-affinity antagonist of human substance P/neurokinin 1 receptors.
The bioavailability is approximately 60% to 65%. Following doses of 125 mg on day 1 and 80 mg on days 2 and 3, the mean C max occurs at approximately 4 h and reaches about 1.5 mcg/mL.
Plasma protein binding is more than 95%. The mean Vd ss is approximately 70 L. Aprepitant crosses the blood-brain barrier.
Data indicate aprepitant is extensively metabolized by CYP3A4 and, to a lesser degree, by CYP1A2 and CYP2C19.
Following IV administration of a single 100 mg dose, 57% was excreted in the urine and 45% in the feces.
No dosage adjustment is necessary for patients with renal function impairment or end-stage renal disease undergoing hemodialysis.Hepatic Function Impairment
No dosage adjustment is necessary in patients with mild or moderate hepatic function impairment.Elderly
No dosage adjustment is necessary in elderly patients.Gender
No dosage adjustment is necessary based on gender.Race
No dosage adjustment is necessary based on race.
In combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin; in combination with other antiemetic agents for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy; prevention of postoperative nausea and vomiting.
Coadministration of astemizole, cisapride, pimozide, or terfenadine; hypersensitivity to any component of the product.
PO 40 mg within 3 h prior to induction of anesthesia.Prevention of Chemotherapy–Induced Nausea and VomitingAdults
PO 125 mg 1 h prior to chemotherapy treatment on day 1 and 80 mg/day in the morning on days 2 and 3. Administer in combination with a corticosteroid and 5-HT 3 antagonist.
Store capsules at 68° to 77°F. Do not remove desiccant from bottle.
Because the efficacy of hormonal contraceptives may be reduced, patients may need an alternative or additional nonhormonal contraceptive.CYP2C9 substrates (eg, phenytoin, tolbutamide, warfarin)
Plasma concentrations of these agents may be reduced. In patients receiving warfarin, monitor the INR in the 2-wk period (especially at 7 to 10 days) after starting aprepitant therapy.CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin)
Plasma concentrations of aprepitant may be reduced, decreasing the therapeutic effect.CYP3A4 inhibitors (eg, clarithromycin, diltiazem, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, troleandomycin)
Plasma concentrations of aprepitant may be elevated, increasing the risk of adverse reactions.CYP3A4 substrates (eg, alprazolam, cisapride, dexamethasone, docetaxel, etoposide, ifosfamide, imatinib, irinotecan, methylprednisolone, midazolam, paclitaxel, pimozide, triazolam, vinblastine, vincristine, vinorelbine)
Plasma concentrations of these agents may be increased. Astemizole, cisapride, pimozide, and terfenadine are contraindicated with coadministration of aprepitant. Reduce the dexamethasone dose by approximately 50%; reduce the IV and oral dose of methylprednisolone by 25% and 50%, respectively, when administering aprepitant.Paroxetine
Plasma levels of aprepitant and paroxetine may be decreased.
None well documented.
Hypotension (6%); bradycardia (4%); hypertension (2%).
Asthenia/fatigue (18%); headache (16%); dizziness (7%); pyrexia (6%); insomnia (4%).
Alopecia (24%); pruritus (8%); hot flush (3%); angioedema, Stevens-Johnson syndrome, urticaria.
Tinnitus (4%); pharyngolaryngeal pain (3%).
Nausea (13%); constipation (12%); anorexia, diarrhea (10%); dyspepsia, vomiting (8%); heartburn, stomatitis (5%); epigastric discomfort, flatulence, gastritis (4%).
Neutropenia (9%); anemia (3%).
Increased proteinuria (7%); increased ALT (6%); increased BUN (5%); increased serum creatinine (4%); and increased AST (3%).
Abdominal pain (5%); fever, mucous membrane disorder (3%).
Monitor patient for antiemetic efficacy.
Category B .
Safety and efficacy not established.
Long-term continuous use for prevention of nausea or vomiting is not recommended.
Copyright © 2009 Wolters Kluwer Health.